I-131 CONTAMINATION FROM THYROID-CANCER PATIENTS

被引:0
|
作者
IBIS, E [1 ]
WILSON, CR [1 ]
COLLIER, BD [1 ]
AKANSEL, G [1 ]
ISITMAN, AT [1 ]
YOSS, RG [1 ]
机构
[1] MILWAUKEE CTY MED CTR,RADIAT SAFETY PROGRAM OFF,MILWAUKEE,WI
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
High-dose radioactive iodine therapy using I-131 is the treatment of choice for patients with thyroid cancer following thyroidectomy. Because of the large amount of activity which is excreted during hospitalization, contamination hazard from I-131 excretion via perspiration, saliva, breath and urine may arise. In eight patients treated with doses of I-131 ranging from 3.7 to 14.8 GBq (1 00-400 mCi), activity levels were measured in room air, from room surfaces, the toilet, the patients' exhaled breath, skin, saliva and toothbrushes, and the gloves used by medical staff. Thyroid bioassays were also performed on medical staff personnel caring for these patients both before and two days after administration of the treatment dose. Removable activity from the skin was positively correlated with treatment dose and reached a maximum at 24 hr post-therapy. Removable activity from room surfaces exceeded the level of contamination which requires clean-up in a restricted area during the patient's hospitalization. Thyroid bioassays on medical staff showed no significant uptake 2 days after treatment. The relatively high activities present in the saliva, urine and on the skin of these patients emphasizes the need for all individuals coming in contact with these patients to be made aware of the contamination hazard present.
引用
收藏
页码:2110 / 2115
页数:6
相关论文
共 50 条
  • [31] THYROID-CANCER AFTER DIAGNOSTIC DOSES OF I-131 - A RETROSPECTIVE COHORT STUDY
    HOLM, LE
    WIKLUND, KE
    LUNDELL, GE
    BERGMAN, NA
    BJELKENGREN, G
    CEDERQUIST, ES
    ERICSSON, UBC
    LARSSON, LG
    LIDBERG, ME
    LINDBERG, RS
    WICKLUND, HV
    BOICE, JD
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (14): : 1132 - 1138
  • [32] TESTICULAR DAMAGE AFTER RADIOACTIVE IODINE (I-131) THERAPY FOR THYROID-CANCER
    HANDELSMAN, DJ
    TURTLE, JR
    CLINICAL ENDOCRINOLOGY, 1983, 18 (05) : 465 - 472
  • [33] DERMATOMYOSITIS ASSOCIATED WITH THYROID-CANCER - FAVORABLE COURSE AFTER I-131 IRRADIATION
    ARCHAMBEAUDMOUVEROUX, F
    BERNARD, P
    LAROUMAGNE, G
    DEJAX, C
    VALLAT, JM
    PRESSE MEDICALE, 1986, 15 (38): : 1928 - 1928
  • [34] HEPATIC VISUALIZATION ON I-131 WHOLE-BODY THYROID-CANCER SCANS
    ZIESSMAN, HA
    BAHAR, H
    FAHEY, FH
    DUBIANSKY, V
    JOURNAL OF NUCLEAR MEDICINE, 1987, 28 (09) : 1408 - 1411
  • [35] PROGNOSTIC FACTORS IN I-131 TREATED THYROID-CANCER BY COX MODEL ANALYSIS
    CHEVALIER, A
    BRIDJI, B
    ASSELAIN, B
    HESHMATI, HM
    VALLEE, G
    JOURNAL DE MEDECINE NUCLEAIRE ET BIOPHYSIQUE, 1988, 12 (03): : 217 - 224
  • [36] A SIMPLIFIED LOW IODINE DIET IN I-131 SCANNING AND THERAPY OF THYROID-CANCER
    LAKSHMANAN, M
    SCHAFFER, A
    ROBBINS, J
    REYNOLDS, J
    NORTON, J
    CLINICAL NUCLEAR MEDICINE, 1988, 13 (12) : 866 - 868
  • [37] RECURRENT THYROID-CANCER ROLE OF SURGERY VERSUS RADIOACTIVE IODINE (I-131)
    COBURN, M
    TEATES, D
    WANEBO, HJ
    ANNALS OF SURGERY, 1994, 219 (06) : 587 - 595
  • [38] THE INFLUENCE OF I-131 THERAPY IN THYROID-CANCER ON THE FUNCTION OF SALIVARY-GLANDS
    DELPRAT, CC
    HOEFNAGEL, CA
    MARCUSE, HR
    ACTA ENDOCRINOLOGICA, 1983, 102 : 73 - 74
  • [39] PARADOXICAL CHANGES IN I-131 SCINTIGRAPHIC FINDINGS IN ADVANCED FOLLICULAR THYROID-CANCER
    KRISHNA, L
    DADPARVAR, S
    BRADY, LW
    MICAILY, B
    MEIHOFER, M
    SLIZOFSKI, WJ
    BROWN, SJ
    CHEVRES, A
    ROMAN, R
    KHAN, AS
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (09) : 1574 - 1576
  • [40] FACTORS AFFECTING I-131 ABLATION OF THYROID REMNANT AFTER THYROIDECTOMY FOR DIFFERENTIATED THYROID-CANCER
    CECCARELLI, C
    MARTINO, E
    LIPPI, F
    GIANCHECCHI, D
    LUCHETTI, F
    BRACCI, E
    PINCHERA, A
    JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES, 1987, 31 (01): : 46 - 46